Navigating Hyperkalaemia- The A-to-H Clinical Strategy

Sourabh Sharma[1], Sanjay Kalra[2]

Abstract

Hyperkalaemia is a life-threatening dyselectrolytaemia which is characterized by elevated serum potassium levels. It needs a systematic and overarching approach to effectively manage a case of hyperkalaemia. We propose a structured A-to-H approach to guide clinicians in managing hyperkalaemia, ensuring that no critical aspect is neglected or inadvertently missed. This approach involves Analytical accuracy, Background, Clinical context, Diagnosis and drugs, Evaluation, Follow-up, Guidelines adherence, and Health education. With this article, we reiterate the need to properly assess and promptly manage a case of hyperkalaemia in various clinical settings, providing detailed explanation of each component of the ABCDEFGH approach.

Keywords: Hyperkalaemia, Potassium, Potassium binders, Prevention, Health evaluation.

DOI: https://doi.org/10.47391/JPMA.25-02

Introduction

Hyperkalaemia is a common form of dyselectrolytaemia which can be life threatening, if untreated, in conditions like cardiovascular disease, chronic kidney disease (CKD), or drug- associated hyperkalaemia[1,2]. Accurate laboratory assessment, prompt therapeutic actions, and comprehensive grasp of the patient's clinical context are necessary to manage hyperkalaemia[1,2]. In this article, we share an ABCDEFGH strategy for treating hyperkalaemia with a focus on its application in clinical practice. The A-to-H strategy is a comprehensive clinical tool which offers a methodical, all-inclusive approach to assessment and treatment of hyperkalaemia, guaranteeing that all important factors are taken into account.

A: Analytical Accuracy

Making sure that potassium readings are analytically accurate is the first step in managing hyperkalaemia. Falsely increased potassium levels (pseudo hyperkalaemia) can result from pre-analytic factors such as haemolysis during blood collection, or analytic factors which include the accuracy and dependability of the laboratory equipment utilised[3,4]. Before making any clinical judgement, clinicians need to be vigilant for analytical errors, and make sure that potassium levels are tested accurately.

B: Background of the Patient

When determining the patient's risk prior to hyperkalaemia management, a complete grasp of their medical history is of uttermost importance. This entails a thorough examination of the patient's dietary habits, with special attention to foods and drinks high in potassium, as well as any other variables influencing potassium intake[1,2,5]. Customising the treatment plan also requires knowing the patient's known comorbidities, baseline renal function, history of CKD, cardiovascular risks, and general health status[1,5].

C: Clinical Context

The accurate management approach must be chosen based on the clinical context of hyperkalaemia. It is necessary to consider various aspects including the patient's medication regimen, comorbidities, underlying illnesses, and urine output[1,2,6]. For instance, a patient with history of CKD could require a different strategy than a patient with adequate renal function. It is important to understand the clinical context of hyperkalaemia to find the underlying aetiology, and identify potential precipitating factors.

D: Diagnosis and Drugs

Crucial elements of this strategy include determining the underlying cause of hyperkalaemia and comprehending the role of drugs. The treating physician must weigh the risks over benefits of keeping patients on drugs that cause hyperkalaemia, like RAAS inhibitors, non-steroidal mineralocorticoid receptor antagonists, etc[7,8]. This section also entails determining the precise cause of hyperkalaemia, such as drug-induced hyperkalaemia, acute or chronic kidney dysfunction, or adrenal insufficiency, and treating these causes appropriately.

E: Evaluation

Evaluation entails figuring out whether an outpatient or inpatient environment is best for managing hyperkalaemia and evaluating its duration and severity[1,2].

[1]Department of Nephrology, VMMC & Safdarjung Hospital, New Delhi, India, [2]Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India

Correspondence: Sanjay Kalra. **Email:** brideknl@gmail.com

ORCID ID: 0000-0003-1308-121X

Table 1: The ABCDEFGH Approach to Hyperkalaemia Management

	Component	Description
A	Analytical Accuracy	Ensuring accurate potassium measurements, considering pre-analytic and analytic factors.
B	Background	Assessing the patient's diet, beverages, renal function, and overall health status.
C	Clinical Context	Evaluating urine output, comorbidities, CKD history, cardiovascular risk, and medications.
D	Diagnosis and Drugs	Identifying underlying causes and assessing the impact of medications.
E	Evaluation	Determining the severity and duration of hyperkalaemia and the appropriate management setting.
F	Follow-up	Scheduling investigations and follow-up visits to monitor and manage potassium levels.
G	Guideline Adherence	Ensuring treatment aligns with the latest clinical guidelines.
H	Health Education	Educating patients on diet, medication adherence, and recognizing symptoms of hyperkalaemia.

The patient's clinical situation should be taken into consideration when determining whether potassium binders or other therapeutic measures are necessary. Short-term versus long-term management techniques vary and should be employed as per clinical context[9,10]. The presence of symptoms, ECG abnormalities, and serum potassium level can all affect how urgent a patient needs to receive therapy[11].

F: Follow-up

In controlling hyperkalaemia, especially in chronic cases, follow-up is crucial element. This entails planning the proper work-up to keep an eye on renal function, potassium levels, and other pertinent factors[1,2]. The degree of hyperkalaemia, the success of the intervention, and the patient's general condition should all be taken into consideration when determining how frequently a patient should follow up. Proper follow-up guarantees that hyperkalaemia is properly controlled and lowers the likelihood of recurrence[1,2].

G: Guidelines Adherence

Clinical guidelines provide standardised methods for detecting and treating hyperkalaemia. Following these recommendations enables medical professionals to make well-informed choices regarding treatment options[12]. For example, following guidelines regarding adherence to RAAS inhibitors and how to adjust their dosage in cases with hyperkalaemia can help CKD patients to maintain drug compliance.[13] Adhering to recommendations also helps to improve patient safety by lowering variation in treatment results and fostering uniformity in care across various healthcare settings.

H: Health Education

The most important part of this strategy is educating the patient and providing proper health counselling regarding hyperkalaemia, its signs and symptoms and strategies to prevent it. It helps preventing recurrence and empowering patients to manage their condition effectively.[14] The likelihood of subsequent episodes can be greatly decreased by teaching patients about the dietary sources of potassium, the significance of medication adherence, and how to identify the symptoms of hyperkalaemia.[1,2] This part entails counselling sessions where patients receive guidance on items to steer clear of, how to check the potassium level on food labels, and why routine follow-ups are essential.

Conclusion

The A-to-H strategy of hyperkalaemia management provides a systematic approach by which clinicians can guarantee a comprehensive assessment and treatment of this potentially fatal illness by attending to each component. This strategy offers an organised way for ongoing care and monitoring, which not only improves patient outcomes but also increases the accuracy of diagnosis and treatment.

Disclaimer: None.

Conflict of Interest: None.

Source of Funding: None.

References

1. Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34(Suppl 3): iii2-iii11.
2. Simon LV, Hashmi MF, Farrell MW. Hyperkalemia. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Sep 24. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470284/
3. Schlüter K, Cadamuro J. Erroneous potassium results: preanalytical causes, detection, and corrective actions. Crit Rev Clin Lab Sci. 2023;60:442-465.
4. Asirvatham JR, Moses V, Bjornson L. Errors in potassium measurement: a laboratory perspective for the clinician. N Am J Med Sci. 2013;5:255-9.
5. Rafique Z, Peacock F, Armstead T, Bischof JJ, Hudson J, Weir MR, Neuenschwander J. Hyperkalemia management in the emergency department: An expert panel consensus. J Am Coll

Emerg Physicians Open. 2021;2: e12572.
6. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26:377-84.
7. Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol Res. 2021; 172:105835.
8. Gregg LP, Navaneethan SD. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Nephrol Dial Transplant. 2023;38:1355-1365.
9. Chaitman M, Dixit D, Bridgeman MB. Potassium-Binding Agents for the Clinical Management of Hyperkalemia. P T. 2016;41:43-50.
10. Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6:CD013165.
11. Raffee LA, Alawneh KZ, Ababneh MJ, Hijazi HH, Al Abdi RM, Aboozour MM, et al. Clinical and electrocardiogram presentations of patients with high serum potassium concentrations within emergency settings: a prospective study. Int J Emerg Med. 2022;15:23.
12. Álvarez-Rodríguez E, Olaizola Mendibil A, San Martín Díez MLÁ, Burzako Sánchez A, Esteban-Fernández A, Sánchez Álvarez E. Recommendations for the management of hyperkalemia in the emergency department. Emergencias. 2022;34:287-297.
13. De Nicola L, Ferraro PM, Montagnani A, Pontremoli R, Dentali F, Sesti G. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors. Intern Emerg Med. 2024;19:295-306.
14. Paterick TE, Patel N, Tajik AJ, Chandrasekaran K. Improving health outcomes through patient education and partnerships with patients. Proc (Bayl Univ Med Cent). 2017 ;30:112-113.